Follistatin vs ACE-031
Natural myostatin-binding glycoprotein vs engineered activin receptor decoy — two approaches to myostatin inhibition for muscle growth and muscular dystrophy research.
Last updated: 2026-03-08
Quick Comparison Table
| Category | Follistatin | ACE-031 |
|---|---|---|
| Molecule Type | Endogenous glycoprotein (315 or 344 amino acids) | Recombinant fusion protein (ActRIIB-Fc) |
| Primary Mechanism | Binds and neutralises myostatin, activins, and other TGF-β ligands | Decoy receptor that traps myostatin, activins, and GDF-11 |
| Selectivity | Broad — binds multiple TGF-β family ligands | Broad — traps multiple ActRIIB ligands |
| Administration | Gene therapy (AAV), SC injection (research) | SC injection (clinical trials) |
| Clinical Status | Gene therapy trials (Nationwide Children's Hospital) | Clinical development paused (safety concerns) |
| Primary Application | Muscle wasting, muscular dystrophy, body composition | Duchenne muscular dystrophy (initial focus) |
| Key Concern | Non-specificity (binds many TGF-β ligands) | Off-target effects (nosebleeds, telangiectasias) |
| Muscle Effect | Significant hypertrophy in preclinical models | Demonstrated muscle mass increase in DMD patients |
Mechanism of Action
Follistatin
Follistatin Mechanism:
Follistatin is a naturally occurring glycoprotein with two main isoforms: FS288 (tissue-bound) and FS315 (circulating). It acts as a natural antagonist of TGF-β superfamily ligands.
Key actions: 1. **Myostatin neutralisation** — Binds and inactivates myostatin (GDF-8), removing its muscle growth inhibition 2. **Activin binding** — Neutralises activin A and B, reducing FSH secretion and muscle catabolism 3. **GDF-11 antagonism** — Blocks GDF-11 signalling 4. **Muscle hypertrophy** — Removes the "brake" on muscle growth, allowing hypertrophy beyond normal limits
Follistatin's role as a myostatin antagonist was dramatically demonstrated in follistatin-overexpressing mice, which developed dramatic muscular hypertrophy, and in Belgian Blue cattle, which have natural follistatin-related mutations.
ACE-031
ACE-031 Mechanism:
ACE-031 is a recombinant fusion protein consisting of the extracellular domain of ActRIIB (activin receptor type IIB) fused to the Fc portion of human IgG1.
Key actions: 1. **Ligand trap** — Acts as a soluble decoy receptor, binding and sequestering myostatin, activins, GDF-11, and other ActRIIB ligands before they can signal through cellular receptors 2. **Muscle growth** — Removing myostatin signalling promotes muscle fibre hypertrophy 3. **Bone effects** — ActRIIB ligand trapping may affect bone metabolism 4. **Broad trapping** — Binds 10+ TGF-β family ligands, not just myostatin
ACE-031 was developed by Acceleron Pharma as a therapeutic for Duchenne muscular dystrophy, leveraging the "ligand trap" approach rather than direct myostatin antibody targeting.
Clinical Trial Evidence
Follistatin Clinical Studies
Participants: 6
Duration: 2 years
AAV1-FS344 gene therapy improved 6-minute walk test by 58 metres and maintained muscle function in Becker muscular dystrophy patients.
Statistically significant
Participants: 0
Duration: Lifespan
Follistatin-overexpressing mice had 117% increase in muscle mass — greater than myostatin knockout alone, confirming additional pathways.
Statistically significant
Participants: 8
Duration: 12 months
AAV1-FS344 showed initial improvement in grip strength and 6MWT in sIBM patients, though some effects waned.
Statistically significant
Participants: 0
Duration: 4 weeks
Recombinant Follistatin-315 injected SC increased muscle mass by 15-20% in mice without exercise.
Statistically significant
Participants: 0
Duration: Chronic
Follistatin overexpression in females caused fertility disruption via activin/FSH suppression. Highlighted non-specificity concern.
Not statistically significant
ACE-031 Clinical Studies
Participants: 12
Duration: 12 weeks
ACE-031 increased lean body mass in DMD patients. However, trial was paused due to vascular side effects.
Statistically significant
Participants: 48
Duration: 29 days
Single dose of ACE-031 increased lean mass by ~1.3kg and decreased fat mass by ~0.5kg in healthy postmenopausal women.
Statistically significant
Participants: 12
Duration: 12 weeks
Nosebleeds, gum bleeding, and telangiectasias observed. Attributed to BMP-9/10 trapping affecting vascular endothelium.
Not statistically significant
Participants: 12
Duration: 12 weeks
MRI analysis showed increased muscle volume and reduced fatty infiltration in DMD patients treated with ACE-031.
Statistically significant
Participants: 48
Duration: 29 days
ACE-031 increased bone formation markers (P1NP, BSAP) suggesting anabolic bone effects alongside muscle effects.
Statistically significant
Benefits Comparison
Follistatin Unique Benefits
- Natural/endogenous protein
- Gene therapy approach for sustained expression
- Dramatic muscle hypertrophy in preclinical models
- Active clinical trials (Nationwide Children's Hospital)
- Additional anti-fibrotic potential
Shared Benefits
- Myostatin inhibition → muscle growth
- Potential for muscular dystrophy treatment
- Body composition improvement
- ActRIIB pathway modulation
ACE-031 Unique Benefits
- Demonstrated lean mass increase in humans (both DMD and healthy)
- Engineered for pharmacological properties
- Bone anabolic effects
- Body composition improvement
- Rapid onset (single dose effects)
Research & Evidence
Follistatin Research
Follistatin research spans decades of basic science. Clinical translation via AAV gene therapy is the most advanced pathway (Jerry Mendell, Nationwide Children's Hospital). The gene therapy approach provides sustained expression but is essentially irreversible.
ACE-031 Research
ACE-031 reached Phase II clinical trials before being paused for safety. Its parent company (Acceleron) pivoted to a related molecule (Luspatercept/Reblozyl) targeting ActRIIA for anaemia — which achieved FDA approval. Lessons from ACE-031 informed more selective next-generation approaches.
Head-to-Head Analysis
Two Approaches, Same Target:
Both Follistatin and ACE-031 ultimately inhibit myostatin signalling, but through different mechanisms: - Follistatin: Natural protein that binds and neutralises myostatin directly - ACE-031: Engineered decoy receptor that traps myostatin before it reaches cell-surface receptors
Non-Specificity Problem: Both bind multiple TGF-β family members beyond myostatin — this broad activity is the source of both additional benefits (muscle effects from activin inhibition) and safety concerns (off-target effects on vasculature, reproductive hormones, etc.).
Clinical Progress: ACE-031 reached Phase II trials for DMD but was paused due to vascular side effects (nosebleeds, telangiectasias from BMP-9/10 trapping). Follistatin gene therapy (AAV-FS344) has been tested in Becker muscular dystrophy patients with promising early results at Nationwide Children's Hospital.
Next Generation: Both have informed next-generation approaches — more selective myostatin antibodies (e.g., SRK-015/Apitegromab) that avoid the non-specificity issues.
Protocol Comparison
Follistatin Protocol
Follistatin Protocols:
Gene Therapy (Clinical): AAV1-FS344 via direct intramuscular injection — one-time administration with sustained expression.
Recombinant Protein (Research): SC injection — doses and schedules not standardised for human use. Research peptide market: Various FS344 products available; quality and purity vary.
⚠️ Note: Gene therapy is irreversible. Recombinant protein is investigational.
ACE-031 Protocol
ACE-031 Protocols (Clinical Trial-Based):
Phase I: Single SC dose of 0.02-3 mg/kg. Phase II (DMD): SC injection every 2 weeks at 1-2.5 mg/kg.
⚠️ Note: Clinical development paused. Not available outside research settings.
Safety Profiles
Follistatin Safety
Follistatin Safety:
Gene therapy: Well-tolerated in clinical trials (6-14 patients). No serious adverse events reported. Anti-AAV antibodies develop (preventing re-dosing).
Theoretical concerns: Non-specific TGF-β ligand inhibition may affect reproductive hormones (activin/FSH), wound healing, and inflammation regulation.
Recombinant protein: Limited human safety data.
ACE-031 Safety
ACE-031 Safety:
Clinical trial safety issues led to development pause: - Nosebleeds and gum bleeding - Telangiectasias (small dilated blood vessels) - Attributed to BMP-9/10 trapping affecting vascular endothelium
These off-target vascular effects were the primary reason for clinical hold. The muscle and bone effects were promising but the safety profile was unacceptable.
The Verdict
Both Follistatin and ACE-031 demonstrate that myostatin inhibition can produce meaningful muscle growth, but both face challenges from non-specificity — trapping multiple TGF-β ligands creates off-target effects. Follistatin gene therapy remains in active clinical development for muscular dystrophies with acceptable safety to date. ACE-031's development was paused but informed successful programmes (Luspatercept). The field is moving toward more selective approaches (myostatin-specific antibodies) that avoid the broad ligand trapping of both molecules.
Frequently Asked Questions
Conclusion
Follistatin and ACE-031 are pioneering myostatin inhibitors that proved the concept of pharmacological muscle growth in humans. Both face the fundamental challenge of non-selectivity — inhibiting multiple TGF-β family members creates off-target effects that limit clinical utility. Follistatin gene therapy remains in active trials for muscular dystrophies. ACE-031's legacy lives on through Luspatercept (Reblozyl), which targets a related receptor for anaemia. The next generation of more selective myostatin inhibitors aims to deliver the muscle benefits without the safety trade-offs.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Follistatin nor ACE-031 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.